Barry Jacobson, MD
Obstetrics & Gynecology · Glen Mills, PANPI 1275679250
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $227,843 of the $301,861 with a category attached, or 75.5%. Amgen accounts for 74.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $166,457 and has fallen 88.5% since, to $19,077 in 2025. Among obstetrics & gynecology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 945 payments — averaging $319.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$224K
- Radius Health, Inc.$76K
- AstraZeneca$496
- Almatica Pharma LLC$276
- Therapeuticsmd, Inc.$203
- AbbVie$203
- plus $732 from 20 others
Across 14 payments — averaging $45.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Radius Health, Inc.$642
What the payments were for
- Consulting fees$9,2753%
- Speaking & faculty fees$227,84375%
- Travel & lodging$47,46316%
- Food & beverage$17,2626%
- Gifts$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 531 | $223,959 |
| Radius Health, Inc. | 306 | $75,991 |
| AstraZeneca | 20 | $496 |
| Almatica Pharma LLC | 23 | $276 |
| Therapeuticsmd, Inc. | 15 | $203 |
| AbbVie | 10 | $203 |
| Kyowa Kirin, Inc. | 10 | $145 |
| UCB, Inc. | 5 | $102 |
| Sage Therapeutics, LLC | 3 | $68 |
| Ultragenyx Pharmaceutical Inc. | 3 | $52 |
| Alvogen Inc | 2 | $45 |
| Millicent US Inc | 2 | $44 |
| Lilly USA, LLC | 2 | $34 |
| Ascendis Pharma Endocrinology Inc | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Kaleo, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Agile Therapeutics, Inc. | 1 | $19 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Mylan Pharmaceuticals Inc. | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Novo Nordisk | 1 | $12 |
| Exeltis, USA Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$301,861 in reported general payments places this provider in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 62 | $185,321 |
| ProliaDenosumab | 19 | $32,345 |
| Raloxifene Hcl | 328 | $17,325 |
| Estradiol (Twice Weekly)Estradiol | 50 | $5,457 |
| Risedronate Sodium | 19 | $1,301 |
| Chlorthalidone | 51 | $909 |
| ProgesteroneProgesterone, Micronized | 18 | $900 |
| Estradiol (Once Weekly)Estradiol | 14 | $789 |
| Hydrochlorothiazide | 143 | $725 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 23 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $75,991 | $185,32162 claims |
| AmgenProlia | $223,959 | $32,34519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Other obstetrics & gynecology in Glen Mills
- Stephen KlaskoPhiladelphia$2.2M
- Stephanie SoberPhiladelphia$1.8M
- Timothy GrubeFrackville$260K
- Russell StankiewiczLewisburg$202K
- Jamille Nagtalon-RamosPhiladelphia$183K
- Timothy DeimlingMechanicsburg$182K
- Gerald HarkinsMechanicsburg$140K
- Kirthik ParthasarathyWest Reading$103K
- Catherine ChappellPittsburgh$94K
- Joseph PatrunoAllentown$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.